RE: Educate me10 Jun 2020 17:32
Mass- you ask if £1 is possible and think back, it was 72p and no where near as advanced on any of the projects, last year.
So, ith 36m shares in issue and a sniff of a contract with a pharma, (well, I leave it up to you to come up with your own figure)
However, t this point what we do have is four drugs that have different interest from different areas and party"s. They are each at different stages, but I believe that (for instance) the Japan pharma would not have signed MTA with Valirx, after having studied in-depth the data for the compound. That is a hugely powerful step forward.
Endomitosis is a very large market and affects many woman, so this has the potential imo to be a blockbuster.
On the other hand you have VAL 101, 201 and 401 that have their interested parties.
Imo, if Val201 has anti -viral properties and is studied not only for Covid, it to could be a blockbuster in a previously unthought of field in medicine.
For me the previous BOD were inching things forward with these drugs to get them to a point where deals could be signed because of successful trial data or proofs of concept. They were using VAL as a host and they were the parasites killing off the company and extracting all the value.
As pointed out a group of shareholders took action (Fred, Valju-...) And now not only has the management changed, but the company and BOD are now working for the shareholders.
I personally think this will do well, but let's get to 10p, 15p, 25p....first and the rest will fall into place